Feed aggregator

Sony Will Ship Its Final Blu-ray Recorders This Month

Slashdot.org - Wed, 02/11/2026 - 10:00
Sony will ship its last batch of Blu-ray recorders this month, according to Kyodo News, ending the company's decades-long run in a product category it helped create. The recorders targeted exclusively the Japanese domestic market, where households used them to record broadcast television. Sony had already stopped manufacturing the devices and recordable discs about a year ago, and the final shipments are clearing out remaining inventory. Kyodo attributes the segment's death to the rise of streaming services. Sony will continue selling Blu-ray players "for the time being." The broader Blu-ray ecosystem remains intact. Asus, LG, and Pioneer still produce PC drives in internal and external USB form factors. Panasonic and Verbatim continue manufacturing Blu-ray media. The format turned 20 last year, having debuted at CES 2006 -- one year before Netflix launched its streaming platform.

Read more of this story at Slashdot.

T-Mobile Will Live Translate Regular Phone Calls Without an App

Slashdot.org - Wed, 02/11/2026 - 09:01
T-Mobile is opening registration today for a beta test of Live Translation, an AI-powered feature that will translate live phone calls into more than 50 languages when it launches this spring. The feature operates at the network level, so it doesn't require any specific app or device -- beta participants simply dial 87 to activate it on a call. T-Mobile President of Technology and CTO John Saw told The Verge that Live Translation works over VoLTE, VoNR and VoWiFi, meaning it isn't limited to 5G. The only requirement is that a T-Mobile customer must initiate the translation. The beta will be free, though T-Mobile has not said whether the feature will eventually be paywalled.

Read more of this story at Slashdot.

Moderna Says FDA Refuses To Review Its Application for Experimental Flu Shot

Slashdot.org - Wed, 02/11/2026 - 07:20
An anonymous reader shares a report: The Food and Drug Administration has refused to start a review of Moderna's application for its experimental flu shot, the company announced Tuesday, in another sign of the Trump administration's influence on tightening vaccine regulations in the U.S. Moderna said the move is inconsistent with previous feedback from the agency from before it submitted the application and started phase three trials on the shot, called mRNA-1010. The drugmaker said it has requested a meeting with the FDA to "understand the path forward." Moderna noted that the agency did not identify any specific safety or efficacy issues with the vaccine, but instead objected to the study design, despite previously approving it. The company added that the move won't impact its 2026 financial guidance. Moderna's jab showed positive phase three data last year, meeting all of the trial goals. At the time, Moderna said the stand-alone flu shot was key to its efforts to advance a combination vaccine targeting both influenza and Covid-19.

Read more of this story at Slashdot.

Syndicate content
Comment